Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14156 | ISIN: GB00BYMT0J19 | Ticker-Symbol: LIA
Frankfurt
25.04.24
08:01 Uhr
51,00 Euro
0,00
0,00 %
1-Jahres-Chart
LIVANOVA PLC Chart 1 Jahr
5-Tage-Chart
LIVANOVA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
51,0052,0019:47

Aktuelle News zur LIVANOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.LivaNova PLC: LivaNova to Announce First-Quarter 2024 Results278LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m....
► Artikel lesen
20.03.LivaNova shares hold as trial ends early on positive results1
20.03.US STOCKS J.Jill, LivaNova, International Paper3
20.03.LivaNova reports positive study results for neuromod for sleep apnea1
20.03.LivaNova's OSPREY trial to conclude early on positive results1
20.03.LivaNova gains after positive predictive outcome of sleep apnea study1
20.03.LivaNova PLC: LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea200LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation,...
► Artikel lesen
06.03.LivaNova prices $300M offering1
06.03.LivaNova PLC: LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029347LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the "notes")...
► Artikel lesen
06.03.LivaNova PLC - 8-K, Current Report-
04.03.LivaNova plans $300 million convertible note offering1
04.03.LivaNova to offer $300M convertible senior notes due1
04.03.LivaNova PLC: LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes288LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the "notes")...
► Artikel lesen
04.03.LivaNova to Present at the Barclays Global Healthcare Conference159LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare...
► Artikel lesen
29.02.LivaNova PLC - 10-K, Annual Report1
22.02.Earnings call: LivaNova sees growth amid ACS wind-down and new leadership2
21.02.LivaNova stock rises on strong Q4, massive bottom-line uptick2
21.02.LivaNova PLC reports results for the quarter ended in December - Earnings Summary1
21.02.LivaNova Surges on Q4 Earnings Beat, FY2024 Outlook In Line With Estimates1
21.02.LivaNova PLC Non-GAAP EPS of $0.87 beats by $0.10, revenue of $310.1M beats by $22.4M1
Seite:  Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1